FDA — authorised 19 January 2021
- Marketing authorisation holder: MERCK SHARP DOHME
- Status: approved
🇺🇸 Verquvo in United States
FDA authorised Verquvo on 19 January 2021
Marketing authorisations
FDA — authorised 10 May 2023
- Application: NDA214377
- Marketing authorisation holder: MSD
- Indication: Labeling
- Status: approved
FDA
- Application: ANDA220221
- Marketing authorisation holder: TORRENT PHARMACEUTICALS LTD
- Local brand name: VERICIGUAT
- Indication: TABLET
- Status: approved
FDA
- Application: ANDA220264
- Marketing authorisation holder: CHANGZHOU PHARMACEUTICAL FACTORY
- Local brand name: VERICIGUAT
- Indication: TABLET
- Status: approved
Verquvo in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Cardiovascular approved in United States
Frequently asked questions
Is Verquvo approved in United States?
Yes. FDA authorised it on 19 January 2021; FDA authorised it on 10 May 2023; FDA has authorised it.
Who is the marketing authorisation holder for Verquvo in United States?
MERCK SHARP DOHME holds the US marketing authorisation.